Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy

Clinical Breast Cancer

Volumn 7, Issue SUPPL. 1, 2007, Pages

  Rugo, Hope S ^a,b,c  

^a Breast Oncology Clinical Trials Program   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aromatase inhibitors; Bone mineral density; Estrogen receptor; Hormone receptor; N telopeptide; Rank ligand

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; CALCIUM; ESTROGEN; EXEMESTANE; GONADORELIN ANTAGONIST; GOSERELIN; LETROZOLE; OSTEOPROTEGERIN; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; TAMOXIFEN CITRATE; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE METABOLISM; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ESTROGEN DEFICIENCY; HORMONAL THERAPY; HUMAN; MONOTHERAPY; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY; POSTMENOPAUSE; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 34548357131     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.s.003     Document Type: Article

References (69)

1. Kanis JA. Pathogenesis of osteoporosis and fracture. In: Kanis JA, ed. Osteoporosis. London: Blackwell Healthcare Communications Ltd; 1997:22-57.
2. Eastell R, Hannon R, Cuzick J. Effect of anastrozole on bone density and bone turnover: results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) study. J Bone Miner Res 2002; 17(suppl 1):S165.
3. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19:3306-3311.
4. Gnant M, Mlineritsch B, Luschin-Soelkner G, et al. Zoledronic acid prevents cancer-treatment induced bone loss in premenopausal women receiving adjuvant endrocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25:820-828.
5. Ghani AN. Bone metabolism: newer perspectives. Malays J Pathol 1997; 19:17-19.
6. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994; 55:273-286.
7. Tanaka S, Nakamura I, Inoue J, et al. Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab 2003; 21:123-133.
8. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305-311.
9. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111:1221-1230.
10. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142:5050-5055.
11. Cecchini MG, Hofstetter W, Halasy J, et al. Role of CSF-1 in bone and bone marrow development. Mol Reprod Dev 1997; 46:75-83.
12. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116:1186-1194.
13. Eriksen EF, Langdahl B, Vesterby A, et al. Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women. J Bone Miner Res 1999; 14:1217-1221.
14. Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996; 2:1132-1136.
15. Jilka RL, Takahashi K, Munshi M, et al. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 1998; 101:1942-1950.
16. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104:719-730.
17. Weitzmann MN, Roggia C, Toraldo G, et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002; 110:1643-1650.
18. Komm BS, Terpening CM, Benz DJ, et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988; 241:81-84.
19. Tomkinson A, Gevers EF, Wit JM, et al. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998; 13:1243-1250.
20. Oursler MJ, Osdoby P, Pyfferoen J, et al. Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci U S A 1991; 88:6613-6617.
21. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005; 208:154-168.
22. Di Gregorio GB, Yamamoto M, Ali AA, et al. Attenuation of the self-renewal of transit-amplifying osteoblast progenitors in the murine bone marrow by 17 beta-estradiol. J Clin Invest 2001; 107:803-812.
23. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11:1043-1051.
24. WHO: World Health Organization technical report: assessment of fracture risk and its applications to screening for postmenopausal osteoporosis - report of a WHO study group. Geneva, Switzerland: World Health Organization; 1994.
25. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-4057.
26. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
27. Boccardo F, Rubagotti A, Puntoni M. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. J Clin Oncol 2005; 23:(16 suppl):10s (Abstract #526).
28. Boccardo F, Guglielmini P, Rubagotti A. Mortality benefit of switching to an aromatase inhibitor in early breast carcinoma: pooled analysis of two consecutive trials. J Clin Oncol 2006; 24(18 suppl):14s (Abstract #548).
29. Coombes R, Paridaens R, Jassem J. First mature analysis of the Intergroup Exemestane Study (IES). J Clin Oncol 2006; 24(18 suppl):9s (Abstract #LBA527).
30. Jakesz R, Gnant M, Greil R. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005; 94: (Abstract #13).
31. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462.
32. Kaufmann M, Jonat W, Hilfrich J. Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. J Clin Oncol 2006; 24(18 suppl):14s (Abstract #547).
33. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25:486-492.
34. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-629.
35. Nordman IC, Spillane AJ, Hamilton AL. The aromatase inhibitors in early breast cancer: who, when, and why? Med J Aust 2005; 183:24-27.
36. Kalidas M, Brown P. Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer 2005; 6:27-37.
37. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19:881-894.
38. Shimodaira K, Fujikawa H, Okura F, et al. Osteoblast cells (MG-63 and HOS) have aromatase and 5 alpha-reductase activities. Biochem Mol Biol Int 1996; 39:109-116.
39. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994; 12:992-997.
40. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852-856.
41. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J Clin Oncol 2006; 24:3629-3635.
42. Coleman R. Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 2006; 24(18 suppl):5s (Abstract #511).
43. Howell A. Analysis of fracture risk factors from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data. J Clin Oncol 2006; 24(18 suppl):18s (Abstract #563).
44. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
45. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8:119-127.
46. Coates A, Keshaviah A, Thurlimann B, et al. Five years of continuous letrozole versus adjuvant endocrine therapy for postmenopausal women with endocrine-responsive breast cancer: further analyses and update of of BIG 1-98. Ann Oncol 2006; 17:ix93-ix113 (Abstract #2410).
47. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23:5126-5137.
48. Coombes RC, Paridaens R, Jassem J. First mature survival analysis of the Intergroup Exemestane Study: a randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. J Clin Oncol 2006; 24(18 suppl):9s (LBA #527).
49. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early breast cancer: a meta-analysis. Lancet Oncol 2006; 7:991-996.
50. Ciccarese M, Bria E, Giannarelli D. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8,794 patients. J Clin Oncol 2006; 24(18 suppl):36s (Abstract #635).
51. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 2005; 97:1262-1271.
52. Lonning PE, Geisler J, Krag L, et al. Changes in bone metabolism after 2 years' treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: follow-up (FU) results of a randomized placebo-controlled study. J Clin Oncol 2005; 23(16 suppl):11s (Abstract #531).
53. Mincey B, Duh M, Thomas S. Risk of cancer treatment-related osteoporosis and fractures among women with breast cancer receiving aromatase inhibitors. J Clin Oncol 2006; 24(18 suppl):17s (Abstract #557).
54. Goss P, Thomsen T, Banke-Bochita J. A randomized, placebo-controlled explorative study to investigate the effect of low estrogen plasma levels on markers or bone turnover in healthy post-menopausal women during the 12-week treatment with exemestane or letrozole. Breast Cancer Res Treat 2002; 76(suppl 1):S76 (Abstract #267).
55. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002; 11:614-621.
56. Heshmati HM, Khosla S, Robins SE et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002; 17:172-178.
57. Subar M, Goss PE, Thomsen T. Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. Proc Am Soc Clin Oncol 2004; 23:734 (Abstract #8038).
58. De Boer R, Burris H, Monnier A. The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol 2006; 24(18 suppl):582s (Abstract #10672).
59. IBCIS. An international multi-centre study of anastrozole versus placebo in postmenopausal women at increased risk of breast cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00078832?order=1 Accessed: January 17, 2007.
60. MAP3. A phase III randomized study of exemestane versus placebo in postmenopausal women at increased risk of developing breast cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00083174?order=1 Accessed: January 17, 2007.
61. Saarto T, Blomqvist C, Virkkunen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19:10-17.
62. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15:955-962.
63. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829-836.
64. Bundred N, Campbell I, Coleman R. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). Presented at: 5th European Breast Cancer Conference; March 21-25, 2006; Nice, France. Abstract #12.
65. Brufsky A, Bundred N, Coleman R. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 2006; 100: (Abstract #107).
66. Van Poznak C, Hannon R, Clack G. The Sabre study: effects of risedronate on bone mineral density and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - first results. Breast Cancer Res Treat 2006; 100: (Abstract #4061).
67. de Ziegler D, Mattenberger C, Luyet C, et al. Clinical use of aromatase inhibitors (AI) in premenopausal women. J Steroid Biochem Mol Biol 2005; 95:121-127.
68. Sverrisdottir A, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004; 22:3694-3699.
69. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185-1194.